Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]
Aileron Therapeutics, Inc. (ALRN)
Last aileron therapeutics, inc. earnings: 11/7 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aileronrx.com
Company Research
Source: Yahoo! Finance
LTI-03 is a novel, Caveolin-1-related peptide that modulates profibrotic activity and sustains critical alveolar epithelial cells. Following inhaled administration of high dose LTI-03 (5 mg BID), a positive trend was observed in seven out of eight biomarkers, with evidence of reduced expression among profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from four biomarkers that were statistically significant in the combined data set of Cohort 1 and Cohort 2, and data from five biomarkers that showed dose dependence relative to the data from those biomarkers in Cohort 1. Overall, the collective findings from this Phase 1b trial provide the company with strong confidence that LTI-03 has the potential to improve lung function and reverse the course of IPF. Surfactant protein D (SPD), an indicator of epithelial cell health that is significantly linked to a decline in lung function, decreased by 5% in Cohort 2 at
Show less
Read more
Impact Snapshot
Event Time:
ALRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALRN alerts
High impacting Aileron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALRN
News
- Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]Seeking Alpha
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsPR Newswire
- Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)PR Newswire
- Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for RetinoblastomaPR Newswire
ALRN
Sec Filings
- 12/9/24 - Form 4
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- ALRN's page on the SEC website